THE PHARMA DEVELOPER'S
GUIDE TO MicroDEP
How non-matrix, micro-depositing architecture achieves microgram-range dosing with 72 to 82% bioavailability
When a compound requires doses below 75 μg, matrix-film architecture leads to content-uniformity failures that tighter manufacturing controls cannot resolve.
MicroDEP changes the architecture entirely by depositing precise API droplets directly onto the film surface, achieving doses as low as 5 μg on the only FDA-approved non-matrix, thin-film platform. Download the guide to understand how the technology works and evaluate whether your compound qualifies.
DOWNLOAD THE GUIDE
How API dispersion through a polymer matrix makes content uniformity failures below 75 μg a structural problem, not a manufacturing one.
Why matrix architecture creates a dose floor
A TECHNICAL RESOURCE FOR PHARMACEUTICAL AND BIOTECH DEVELOPMENT TEAMS
The Pharma Developer's Guide to MicroDEP gives development and BD teams the basis to evaluate whether their compound's dose requirements put matrix films out of reach and what a viable path forward looks like. Drawing on ARx's experience across multiple FDA-approved programs and commercial production exceeding 100 million units annually, this guide covers the full picture from architecture through commercial scale.
Inside, you’ll discover:
FIND OUT IF YOUR COMPOUND IS A CANDIDATE
If your compound's dose requirements put matrix films out of reach, explore whether MicroDEP is the right path for your program.
Which APIs & therapeutic areas benefit most
How MicroDEP delivers from film to bloodstream
What capable micro-depositing development requires
How ARx takes programs from feasibility to commercial scale
Why direct API deposition at the mucosal absorption site reaches peak plasma concentration in 15 to 30 minutes without first-pass hepatic metabolism.
Why ultra-low dose compounds in the 5-500 μg range and branded oral products nearing patent expiration are the strongest MicroDEP candidates.
Why content uniformity validation and QbD documentation for non-matrix architecture differ from conventional oral dosage form standards.
How ARx takes programs from feasibility to commercial scale
What capable micro-depositing development requires
Why end-to-end development under one roof eliminates the timeline risk that comes with transferring a complex program between facilities.
THE PHARMA DEVELOPER'S GUIDE TO MicroDEP
How non-matrix, micro-depositing architecture achieves microgram-range dosing with 72 to 82% bioavailability
When a compound requires doses below 75 μg, matrix-film architecture leads to content-uniformity failures that tighter manufacturing controls cannot resolve.
MicroDEP changes the architecture entirely by depositing precise API droplets directly onto the film surface, achieving doses as low as 5 μg on the only FDA-approved non-matrix, thin-film platform. Download the guide to understand how the technology works and evaluate whether your compound qualifies.
